Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes

References

• Brittenham GM. Disorders of iron metabolism: iron deficiency and overload. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, et al., eds. Hematology: basic principles and practise, 3rd ed. New York: Churchill Livingstone, 2000:397–428.
   Google Scholar
• McCance RA, Widdowson EM. Absorption and excretion of iron. Lancet 1937;ii:680–4.
   Google Scholar
• Deugnier Y, Charalambous P, Le Quilleuc D, Turlin B, Searle J, Brissot P, et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 1993; 18:1363–9.
   PubMed Web of Science ®Google Scholar
• Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, Fraumeni JF. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995; 60:160–2.
   PubMed Web of Science ®Google Scholar
• Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986–95.
   PubMed Web of Science ®Google Scholar
• Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005;57:547–83.
   PubMed Web of Science ®Google Scholar
• Soyano A, Chinea M, Romano EL. The effect of desferrioxamine on the proliferative response of rat lymphocytes stimulated with various mitogens in vitro. Immunopharmacology 1984;8:163–9.
   PubMed Web of Science ®Google Scholar
• Polson RJ, Jenkins R, Lombard M, Williams AC, Roberts S, Nouri-Aria K, et al. Mechanisms of inhibition of mononuclear cell activation by the iron-chelating agent desferrioxamine. Immunology 1990;71:176–81.
   PubMed Web of Science ®Google Scholar
• Richardson DR, Milnes K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1997;89:3025–38.
   PubMed Web of Science ®Google Scholar
• Chenoufi N, Baffet G, Drénou B, Cariou S, Desille M, Clément B, et al. Deferoxamine arrests in vitro the proliferation of porcine hepatocyte in G1 phase of the cell cycle. Liver 1997;18:60–7.
   Google Scholar
• Rakba N, Loyer P, Gilot D, Delcros JG, Glaise D, Baret P, et al. Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis 2000;21:943–51.
   PubMed Web of Science ®Google Scholar
• Richardson DR. Potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol 1997;75:1164–80.
   PubMed Web of Science ®Google Scholar
• Hann HWL, Stahlhut MW, Blumberg BS. Iron mutation and tumor growth: decreased tumor growth in iron deficient mice. Cancer Res 1988;48:4168–70.
   PubMed Web of Science ®Google Scholar
• Le NT, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochem Biophys Acta 2002; 1603:31–46.
   PubMed Web of Science ®Google Scholar
• Chaston TB, Richardson DR. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity and toxicity. Am J Hematol 2003;73:200–10.
   PubMed Web of Science ®Google Scholar
• Richardson DR. Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol 2002;42:267–81.
   PubMed Web of Science ®Google Scholar
• Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, et al. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem 2006;49:6510–21.
   PubMed Web of Science ®Google Scholar
• Gao J, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents: IV. The mechanisms involved in inhibiting cell-cycle progression. Blood 2001;98:842–50.
   PubMed Web of Science ®Google Scholar
• Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, et al. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 2000;59:938–91.
   Web of Science ®Google Scholar
• Brodie C, Siriwardana G, Lucas J, Schleicher R, Terada N, Szepesi A, et al. Neuroblastoma sensitivity to growth inhibition by desferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res 1993;53:3968–75.
   PubMed Web of Science ®Google Scholar
• Glickstein H, Breuer W, Loyevsky M, Konijn AM, Shanzer A,Cabantchik ZI. Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells. Blood 1996;87:4871–8.
   PubMed Web of Science ®Google Scholar
• Valle P, Timeus F, Piglione M, Rosso P, di Montezemolo LC, Crescenzio N, et al. Effect of different exposures to desferrioxamine on neuroblastoma cell lines. Pediatr Hematol Oncol 1995;12:439–46.
   PubMed Web of Science ®Google Scholar
• Selig RA, White L, Gramacho C, Sterlinglevis K, Fraser IW, Naidoo D. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res 1998;58:473–8.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992;79:2741–8.
   PubMed Web of Science ®Google Scholar
• Al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorges GJ. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 1992;80:593–9.
   PubMed Web of Science ®Google Scholar
• Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994;83:2329–33.
   PubMed Web of Science ®Google Scholar
• Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol 2002;15:329–68.
   PubMed Web of Science ®Google Scholar
• Lescoat G, Chantrel-Groussard K, Pasdeloup N, Nick H, Brissot P, Gaboriau F. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell proliferation 2007;40:755–67.
   PubMed Web of Science ®Google Scholar
• Lovejoy D, Richardson DR. Novel “hybrid” iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate high anti-proliferative activity that is selective for tumor cells. Blood 2002;100:666–76.
   PubMed Web of Science ®Google Scholar
• Bergeron RJ, Wiegand J, McManis JS, Bharti N. The design, synthesis and evaluation of organ-specific iron chelators. J Med Chem 2006; 49:7032–43.
   PubMed Web of Science ®Google Scholar
• Liu ZD, Hider RC. Design of iron chelators with therapeutic application. Coord Chem Rev 2002;232:151–71.
   Web of Science ®Google Scholar
• Liu ZD, Hider RC. Design of clinically useful iron-selective chelators. Med Res Rev 2002;22: 26–64.
   PubMed Web of Science ®Google Scholar
• Sansone F, Segura M, Ungaro R. Calixarenes in bioorganic and biomimetic chemistry. In: Asfari Z, Böhmer V, Harrowfield J, Vicens J, eds. Calixarenes 2001. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2001:496–512.
   Google Scholar
• Mutihac L. Functionalized calix[n]arenes as membrane transporters for biological compounds. A minireview. Curr Drug Discov Technol 2008;5:98–104.
   PubMedGoogle Scholar
• Jose P, Menon S. Lower-rim substituted calixarenes and their applications. Bioinorg Chem Appl 2007:65815.
   PubMed Web of Science ®Google Scholar
• Gutsche CD. Calixarenes: Monographs in Supramolecular Chemistry. London: Royal Society of Chemistry, 1989.
   Google Scholar
• Asfari Z, Böhmer V, Harrowfield J, Vicens J, eds. Calixarenes 2001. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2001.
   Google Scholar
• Creaven, BS, Donlon DF, McGinley J. Coordination chemistry of calix[4]arene derivatives with lower rim functionalisation and their applications. Coord Chem Rev 2009;253:893–962.
   Web of Science ®Google Scholar
• Ali A, Salunke-Gawali S, Rao CP, Linares J. A first report of the complexes of 5,11,17,23-tetra-tert-butyl-25,27-dicarboxymethoxy-26,28-dihydroxycalix[4]arene with Mn(II), Fe(III), Co(II), Ni(II), Cu(II) and Zn(II). Inorg Chem Commun 2004;7:1298–301.
   Web of Science ®Google Scholar
• Deligoz H, Ozen O, Cilgi GK. Structural analysis of calix[n]arene-iron (III) complexes (n = 4, 6, 8) and thermal decomposition of the parent calix[n]arenes. J Coord Chem 2007;60:73–83.
   Web of Science ®Google Scholar
• Ogden MI, Skelton BW, White AH. Syntheses, structural studies and solution properties of iron complexes of some amide-substituted calixarenes. J Chem Soc Dalton Trans 2001;20:3073–7.
   Google Scholar
• Guillon J, Léger JM, Sonnet P, Jarry C, Robba M. Synthesis of cone, partial-cone and 1,3-alternate 25,27-bis[1-(2-ethyl)hexyl]- and 25,27-bis[1-(2-tert-butoxy)ethyl]calix[4]arene-crown-6 conformers as potential selective cesium extractants. J Org Chem 2000;65:8283–9.
   PubMed Web of Science ®Google Scholar
• Guillon J, Sonnet P, Malval JP, Massip S, Gosse I, Léger JM, et al. Synthesis and cesium binding affinity of new 25,27-bis(alkyloxy)calix[4]arene-crown-6 conformers in relation to the alkyl pendent moiety. Supramol Chem 2002;14:437–50.
   Web of Science ®Google Scholar
• Guillon J, Léger JM, Dapremont C, Denis LA, Sonnet P, Massip S, et al. First synthesis of 1,3-alternate 25,27-dialkyloxy-5,17-diarylcalix[4]arenes-crown-6 as new cesium selective extracants by Suzuki cross-coupling reaction. Supramol Chem 2004;16:319–29.
   Web of Science ®Google Scholar
• Pires VS, Gaboriau F, Guillon J, Nascimento S, Dassonville A, Lescoat G, et al. Modulation of cell proliferation in rat liver cell cultures by new calix[4]arenes. J Enzyme Inhib Med Chem. 2006;21:261–70.
   PubMed Web of Science ®Google Scholar
• Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 2002;99:15655–60.
   PubMed Web of Science ®Google Scholar
• Troadec MB, Glaise D, Lamirault G, Le Cunff M, Guerin E, Le Meur N, et al. Hepatocyte iron loading capacity is associated with differentiation and repression of motility in the HepaRG cell line. Genomics 2006;87:93–103.
   PubMed Web of Science ®Google Scholar
• Rouan MC, Marfil F, Mangoni P, Sechaud R, Humbert H, Maurer G. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl 2001;755:203–13.
   PubMed Web of Science ®Google Scholar
• Collins EM, McKervey A, Madigan E, Moran MB, Owens M, Ferguson G, et al. Chemically modified calix[4]arenes. Regioselective synthesis of 1,3-(distal) derivatives and related compounds. X-ray crystal structure of a diphenol-dinitrile. J Chem Soc Perkin Trans 1 1991:3137–42.
   Google Scholar
• Collins EM, McKervey A, Harris SJ. Molecular receptors with calix[4]arene substructure. Synthesis of derivatives with mixed ligating functional groups. J Chem Soc Perkin Trans 1 1989:372–4.
   Google Scholar
• Supplementary X-ray crystallographic data of compounds 3c and 8b (CCDC-706418 and CCDC-706417): Cambridge Crystallographic Data Centre, University Chemical Laboratory, 12 Union Road, Cambridge, CB2 1EZ, UK. E-mail: [email protected].
   Google Scholar